Every Form 4 that Kardigan, Inc. (KARD) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow KARD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KARD filings page.
Entities affiliated with Perceptive Advisors reported an indirect acquisition of 20,706 restricted stock units (RSUs) tied to Kardigan, Inc. common stock. The RSUs are director compensation for Douglas E. Giordano’s board service and vest in full on June 17, 2028, subject to his continuous service. The reporting entities and Joseph Edelman may be deemed to have an indirect pecuniary interest through a management fee offset but disclaim beneficial ownership except to that extent.
Kardigan, Inc. reported a large insider purchase by an affiliated investment fund. On June 22, 2026, HRTG PV, L.P., a ten percent owner, made an open‑market purchase of 3,125,000 shares of common stock at $16.00 per share, held indirectly. After this trade, HRTG PV, L.P. held 14,866,868 shares, and HRTG CIF 2024, L.P. held 2,050,166 shares. HRTG GPE, LLC is general partner of both funds, and its managing members Keith Johnson and Kevin Kelly disclaim beneficial ownership beyond any pecuniary interest.
Kardigan, Inc. director and 10% owner Paul L. Berns reported an indirect open-market purchase by ARCH Venture Fund XIII, L.P. of 1,250,000 shares of common stock at $16.00 per share. After this transaction, ARCH’s indirect holdings totaled 15,042,035 shares, while Berns directly held 20,706 shares.
ARCH Venture Fund XIII, L.P., an entity associated with ARCH Venture Partners, reported an open-market purchase of 1,250,000 shares of Kardigan, Inc. common stock at $16.00 per share. After this transaction, ARCH Venture Fund XIII, L.P. held 15,042,035 shares indirectly.
The shares are directly held by ARCH Venture Fund XIII, L.P., with related ARCH entities and certain investment committee members, including directors of Kardigan, potentially deemed beneficial owners but each disclaiming beneficial ownership beyond any pecuniary interest.
Kardigan, Inc. insiders associated with HRTG funds converted multiple series of redeemable convertible preferred stock into Common Stock on June 17, 2026. The Series A, Series B and Series B-1 preferred shares all automatically converted into Common Stock on a 1.5928-to-1 basis when Kardigan’s Form S-1 registration statement became effective, without additional cash payment. Following these conversions, HRTG PV, L.P. held 11,741,868 Common Stock shares indirectly and HRTG CIF 2024, L.P. held 2,050,166 shares indirectly. The filing reports derivative conversions only, with no open-market purchases or sales.
Kardigan, Inc. reported that investment entity ARCH Venture Fund XIII, L.P. converted its preferred equity into common stock in connection with Kardigan’s initial public offering. On June 17, 2026, all Series A, Series B, and Series B-1 Preferred Stock automatically converted into common shares on a 1.5928-for-1 basis upon effectiveness of Kardigan’s Form S-1, with no cash paid. Following these conversions, ARCH Venture Fund XIII, L.P. indirectly holds 13,792,035 shares of Common Stock. The filing notes that related ARCH entities and investment committee members may be deemed beneficial owners but disclaim beneficial ownership beyond any pecuniary interest.
Pasternak Andy reported acquisition or exercise transactions in this Form 4 filing.
Kardigan, Inc.'s Chief Strategy Officer Andy Pasternak received a grant of 79,640 restricted stock units, each representing one share of common stock at no purchase price. These RSUs vest in full on June 17, 2028, contingent on his continued service, and equal his reported direct holdings after the grant.
Meeker David P reported acquisition or exercise transactions in this Form 4 filing.
Kardigan, Inc. director David P. Meeker received an equity grant of 20,706 restricted stock units (RSUs). Each RSU represents the right to receive one share of Kardigan common stock at a later date rather than cash today.
The RSUs vest in full on June 17, 2028, as long as Meeker continues to provide service to the company through that date. Following this award, he is reported as holding 20,706 shares or share-equivalent units directly, reflecting a compensation-related equity grant rather than an open-market purchase or sale.
Kardigan, Inc. director and 10% owner Paul L. Berns reported equity acquisitions tied to Kardigan’s initial public offering and a new board grant. He received 20,706 shares of Common Stock at no cost as a restricted stock unit award, with all RSUs vesting on June 17, 2028, subject to continuous service.
In connection with the IPO, ARCH Venture Fund XIII, L.P., an investment fund associated with Berns, converted its Series A, Series B and Series B-1 Preferred Stock into 13,792,035 shares of Common Stock on a 1.5928-for-1 basis, automatically and without payment of consideration. These shares are held by ARCH XIII, with related general partners and committee members, including Berns, potentially deemed beneficial owners subject to pecuniary-interest limitations.
Moriarty John B reported acquisition or exercise transactions in this Form 4 filing.
Kardigan, Inc. reported that Chief Legal Officer John B. Moriarty received an equity award in the form of 47,784 shares of common stock, represented by restricted stock units. The grant was made at a stated price of $0.00 per share as a compensation award rather than a market purchase.
Each restricted stock unit represents a contingent right to receive one share of common stock upon settlement. The units vest in full on June 17, 2028, provided Moriarty remains in continuous service with the company through that vesting date. Following this grant, he directly holds 47,784 shares subject to these vesting conditions.
Jahn Brianne reported acquisition or exercise transactions in this Form 4 filing.
Kardigan, Inc. reported that its Chief Financial Officer, Brianne Jahn, received a grant of 79,640 shares of common stock in the form of restricted stock units. The award was granted at no cash cost per share and is compensation rather than an open-market purchase.
The RSUs vest in full on June 17, 2028, as long as the executive remains in continuous service through that date. After this grant, the filing shows total direct holdings of 79,640 common shares tied to this award.
Popovits Kimberly J reported acquisition or exercise transactions in this Form 4 filing.
Kardigan, Inc. director Kimberly J. Popovits received an equity award of 20,706 restricted stock units. Each RSU represents a contingent right to receive one share of Kardigan common stock upon settlement. The RSUs vest in full on June 17, 2028, if she remains in continuous service through that date, and her direct holdings after this grant are 20,706 shares-equivalent.
Kardigan, Inc. director Timothy P. Walbert reported receiving new equity awards consisting of restricted stock units and stock options as part of his compensation. He was granted 20,706 RSUs, each representing one share of common stock that vests in full on June 17, 2028, assuming he continues in service through that date. He also received stock options covering 57,573 shares of common stock at an exercise price of $16.00 per share, vesting in 36 equal monthly installments starting June 17, 2026 and expiring on June 16, 2036. After these awards, his reported direct holdings from this grant are 20,706 shares of common stock and options for 57,573 shares.
Kardigan, Inc.’s President & CEO, Anastasios Gianakakos, reported multiple conversions of preferred stock into common shares linked to his spouse and family trusts. On June 17, 2026, Series A and Series B Preferred Stock automatically converted to common stock upon the effectiveness of Kardigan’s Form S‑1 for its initial public offering, on a 1.5928‑for‑1 basis and without any cash payment.
Following these conversions, entities associated with the CEO report indirect holdings including 5,665,090 common shares by AEG 2021 Trust, 2,422,520 shares by KCM 2023 Trust, 498,692 shares by his spouse, 1,165,732 shares by MJA Legacy Trust, and 4,778 shares by the Katina Mandas 2024 Qualified Annuity Trust, plus 49,821 shares held directly. The CEO disclaims beneficial ownership of the trust and spouse holdings except to the extent of any pecuniary interest.
Kardigan, Inc. director Douglas E. Giordano received an equity grant of 20,706 shares of Common Stock in the form of restricted stock units. The award was granted at no cash cost to him and represents his entire reported direct holding of 20,706 shares after the transaction.
Each RSU converts into one share of Common Stock upon settlement and is scheduled to vest in full on June 17, 2028, if he remains in continuous service through that date. This filing reflects a routine compensation-related grant rather than an open-market purchase or sale.
Kardigan, Inc.’s Chief Medical Officer Jay Edelberg reported equity-related acquisitions rather than open-market trades. On June 17, 2026, he received 47,784 shares of Common Stock in the form of restricted stock units granted at no cash cost, and a separate transaction shows 61,268 shares of Series B Preferred Stock converting into 97,587 shares of Common Stock in connection with the company’s initial public offering.
The filing also reports 4,459,840 shares of Common Stock held indirectly by Edelberg Family Ventures, LLC, for which he disclaims beneficial ownership except for any pecuniary interest.